GLP-1 Daily: Ozempic & Wegovy News is a weekday briefing on GLP-1 drugs for patients and anyone about to start one. In about eight minutes, anchor Cassidy and cohost Silvara cover what changed today across semaglutide and tirzepatide: Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus and the new oral GLP-1 pills. Expect FDA decisions, clinical trial readouts, supply and shortage updates, safety and side-effect news, and the cost and access story: prior authorization, insurance and Medicaid coverage, employer plans and compounding-pharmacy enforcement. Every efficacy figure is cited, company-reported data is flagged as such, and each story comes back to one question: does this change what you should ask your clinician? No celebrity weight-loss content, before-and-after photos or miracle claims. Not affiliated with Novo Nordisk or Eli Lilly.
Wegovy Liver-Fat Data at EASD 2026, and What the Wegovy Pill Changes — October 12, 2026
Novo Nordisk's post hoc STEP UP analysis at EASD 2026 says Wegovy brought liver fat below 5 percent in 23 of 26 adults with obesity. We weigh that small, company-presented result and what the oral Wegovy pill does and doesn't change for patients.
In this episode:
Top stories:
1. Wegovy reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat at EASD2026 - Novo - Medical Update Online — Medical Update Online
https://medicalupdateonline.com/2026/10/wegovy-reduced-liver-fat-to-normal-levels-in-9-out-of-10-adults-with-obesity-and-excess-liver-fat-at-easd2026-novo/
2. Step Back: Now that the FDA has approved an oral version of Wegovy, what actually changes for patients compared with the weekly injection—and what still depends on insurance coverage, prescribing decisions, and longer-term evidence?
Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com
9 Oct 2026
Lilly's Oral GLP-1 Orforglipron Clears Heart-Safety Bar in ACHIEVE-4 — October 09, 2026
Eli Lilly's once-daily oral GLP-1 orforglipron showed no excess cardiovascular risk against insulin glargine in the 2,749-patient ACHIEVE-4 trial, published in The Lancet. That clears a key regulatory hurdle, while an NEJM perspective warns that obesity drug trials aren't built to detect emerging harms.
In this episode:
Top stories:
1. Step Back: With the FDA warning Empower Pharmacy over what it calls an “inordinate” number of copies of weight-loss drugs, how does the agency distinguish lawful compounding for individual patients from an impermissible copy—and what should patients ask their prescriber or pharmacy to understand which kind they’re receiving?
2. Major trial confirms CVD safety of oral GLP‑1RA — The Limbic
https://thelimbic.com/cardiology/major-trial-confirms-cvd-safety-of-oral-glp%e2%80%911ra/
3. NEJM Interview: Sarah Schmitz on protections for people enrolled in trials of investigational agents for obesity. — Exa
https://exa.ai/library/podcast/dzktp1g06zm/episode/rhfh2kxfhx7
Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com
8 Oct 2026
GLP-1 Users Lost Sight in the Second Eye Sooner, Ophthalmology Study Finds as Vision-Loss Lawsuits Grow — October 08, 2026
An American Academy of Ophthalmology meeting study links GLP-1 use to faster second-eye NAION, as federal eye-injury cases climb to 247; plus Medicare Bridge paperwork gaps for cash-pay patients, pharmacists seeing more cash GLP-1 fills, the WHO's first childhood obesity guidelines, and Korea's first homegrown GLP-1 obesity drug.
In this episode:
1. GLP-1 Drugs Linked to Faster Vision Loss in the Second Eye, New Study Finds | Newswise — American Academy of Ophthalmology (AAO
https://www.newswise.com/articles/glp-1-drugs-linked-to-faster-vision-loss-in-the-second-eye-new-study-finds
2. Medicare’s Missing On-Ramp For Access To GLP-1s For Weight Management | Health Affairs — T. Joseph Mattingly II
https://www.healthaffairs.org/content/forefront/medicare-s-missing-ramp-access-glp-1s-weight-management
3. Patients increasingly bypass insurance to pay cash for GLP-1 prescriptions, pharmacists say — Bill Schiffner
https://chaindrugreview.com/patients-increasingly-bypass-insurance-to-pay-cash-for-glp-1-prescriptions-pharmacists-say/
4. Should kids living with obesity be on GLP-1s? New global guidance says yes — in some cases — CBC News
https://www.cbc.ca/lite/story/9.7371490
5. MFDS approves Hanmi's EPPE, Korea's first homegrown GLP-1 obesity drug · Local Chorus — Local Chorus
https://localchorus.com/story/20261007-kr-ffvtjtxj
Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com
7 Oct 2026
Medicare's $50 GLP-1 Bridge Leaves Out Some Sick Seniors — October 07, 2026
Medicare's $50-a-month GLP-1 Bridge pilot is denying some obese seniors who have certain diagnoses, such as severe sleep apnea. Separately, Amylyx will present Phase 3 avexitide data for post-bariatric hypoglycemia at ObesityWeek in November.
In this episode:
Top stories:
1. Amylyx to Present Phase 3 LUCIDITY Data at ObesityWeek | AMLX Stock News — Stock Titan
https://www.stocktitan.net/news/AMLX/amylyx-pharmaceuticals-to-present-topline-data-from-phase-3-lucidity-hre4m1zcnakv.html
2. The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify | Sleep Review — Sleep Review
https://sleepreviewmag.com/sleep-treatments/pharmaceuticals/prescription-drugs/medicare-glp-1-discount-not-sleep-apnea/
Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com
6 Oct 2026
Federal Plans Tie 2027 GLP-1 Coverage to Behavioral Therapy as Diabetes Guidelines Move GLP-1s Up Front — October 06, 2026
Federal employee health plans will require documented intensive behavioral therapy before and during anti-obesity drug treatment in 2027, while the new ADA-EASD consensus backs GLP-1 or SGLT2 drugs early in type 2 diabetes. Plus a phase 3 oral GLP-1 pill, a new SELECT heart analysis, and what's known about GLP-1s in children.
In this episode:
1. 2027 FEHB Changes: Weight Loss Drug Rules, A New FSA Card, And Plans Leaving | FedSmith.com — Ian Smith
https://www.fedsmith.com/2026/10/05/2027-fehb-plan-changes/
2. The 2026 Diabetes Consensus Backs GLP-1 or SGLT2 Drugs Early, Possibly From Diagnosis, Without Waiting on Metformin | Peptide News Digest — Peptide News Digest
https://peptidenewsdigest.org/insights/ada-easd-2026-type-2-diabetes-consensus-glp1-sglt2-earlier/
3. Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial | Nature Medicine — Nature Medicine
https://www.nature.com/articles/s41591-026-04713-y
4. Semaglutide heart benefits not fully explained by weight loss - The Pharmacist — Victoria Vaughan
https://www.thepharmacist.co.uk/clinical/nutrition-and-gastroenterology/semaglutide-heart-benefits-not-fully-explained-by-weight-loss/
5. Weight loss GLP-1s are everywhere and kids are taking them too. 7 things parents should know – PolitiFact — Madison Czopek
https://politifact.com/article/2026/oct/05/glp1-weight-loss-children-obesity-risks-parents/
Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com
5 Oct 2026
Rhode Island Joins the Medicaid GLP-1 Cutbacks as Massachusetts Weight-Loss Use Falls 52% — October 05, 2026
Rhode Island Medicaid stopped covering GLP-1s prescribed only for weight loss on October 1, and new Massachusetts data shows weight-loss use fell 52% after insurers pulled back. Plus Cigna employees pressing their own employer, a physician's case against the compounding market, and semaglutide's benefits across frailty levels.
In this episode:
1. Rhode Island Medicaid Ends Coverage of Wegovy,… — Inkl
https://www.inkl.com/news/rhode-island-medicaid-ends-coverage-of-wegovy-zepbound-and-other-glp-1-drugs-prescribed-only-for-weight-loss
2. GLP-1 use for weight loss plunges 52% in Massachusetts after insurers cut coverage — Morgan Taylor
https://www.thecooldown.com/green-business/massachusetts-glp-1-weight-loss-insurers-coverage-cut/
3. OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage — PR Newswire
https://www.prnewswire.com/news-releases/oac-calls-on-cigna-to-listen-to-employees-and-restore-glp-1-coverage-302896674.html
4. I'm an obesity expert and can't wait for the compounding craze to stop | Fortune — Adonis Saremi
https://fortune.com/2026/10/03/fda-compounded-glp1-telehealth-enforcement/
5. Semaglutide Demonstrates Benefits Across Frailty Levels | Obesity | JAMA | JAMA Network — Samantha Anderer
https://jamanetwork.com/journals/jama/fullarticle/2854954
Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com
2 Oct 2026
A $75 Copay Cliff for GLP-1 Adherence as New Mexico's Medicaid Ozempic Bill Climbs — October 02, 2026
A JAMA Health Forum study finds GLP-1 nonadherence tops 80% once monthly out-of-pocket costs pass $75, while New Mexico's Medicaid Ozempic spending hit $38.7 million in 2025. Plus survodutide's Phase 3 in NEJM, the amylin tolerability tradeoff, and Novo's injection-to-pill switch data.
In this episode:
1. Higher GLP-1 costs lead to lower adherence | EurekAlert! — EurekAlert!
https://www.eurekalert.org/news-releases/1146075
2. Ozempic driving massive increase in New Mexico Medicaid prescription drug spending | Local News | santafenewmexican.com — Margaret O'Hara mohara@sfnewmexican.com
https://www.santafenewmexican.com/news/local_news/ozempic-driving-massive-increase-in-new-mexico-medicaid-prescription-drug-spending/article_e6553183-168b-442c-9fdf-2d9fe8f1197c.html
3. Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes - BioSpace — BioSpace
https://www.biospace.com/press-releases/zealand-pharma-announces-boehringer-ingelheims-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-diabetes
4. Novel amylin drug confers 10% weight loss, well tolerated — Dorothy Brooks
https://www.medicaldaily.com/eloralintide-tirzepatide-eloratzp-phase-2-type-2-diabetes-easd-2026-479396
5. People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026 — Annika Kim Constantino
https://www.cnbc.com/2026/09/30/novo-wegovy-pill-weight-loss-injections.html
Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com
1 Oct 2026
Zepbound Returns to CVS Caremark as Massachusetts Faces Equity Pushback on GLP-1 Cuts — October 01, 2026
Zepbound is back on CVS Caremark's standard commercial formulary starting October 1, but employers still decide, while Massachusetts critics press the state to undo its GLP-1 weight-loss coverage cuts. Plus a JAMA Health Forum Medicaid study on prior authorization, Lilly-sponsored ACHIEVE-4 heart-safety data for Foundayo in The Lancet, and California's new CalRx GLP-1 law.
In this episode:
1. CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment — Skinnyvip
https://skinnyvip.com/blog/cvs-caremark-zepbound-formulary-october-2026-what-to-ask-hr/
2. Critics say GLP-1 coverage shift raises equity issues — The Boston Globe
https://www.bostonglobe.com/2026/09/30/business/critics-glp1-coverage-equity/
3. Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version — Drugtopics
https://www.drugtopics.com/view/medicaid-coverage-of-obesity-glp-1s-may-shift-from-diabetes-version
4. Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study — EurekAlert!
https://www.eurekalert.org/news-releases/1145870
5. Newsom signs law allowing California-made GLP-1 drugs — Redding
https://www.redding.com/story/news/health/2026/09/29/california-clears-path-for-generic-glp-1-weight-loss-drugs/92010935007/
Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com
30 Sept 2026
Counterfeit Ozempic Indictment Lands as Retatrutide Data Hits EASD — September 30, 2026
Counterfeit Ozempic allegedly sourced from China is at the center of a federal indictment of two Indian nationals in Tampa. At EASD in Milan, Lilly-funded Phase 3 retatrutide results appear in The Lancet, and a Novo-funded registry study finds no semaglutide–pancreatic cancer link.
In this episode:
Top stories:
1. Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme | The Front Page — The Front Page
https://frnt.com/story/67170/two-indicted-in-florida-for-international-counterfeit-ozempic-smuggling-scheme
2. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes — Finviz
https://finviz.com/news/396798/lillys-triple-agonist-retatrutide-delivered-substantial-weight-loss-and-a1c-reduction-underscoring-its-potential-promise-for-people-with-obesity-and-type-2-diabetes
3. Novo, Lilly unleash dueling GLP-1 datasets at EASD in Milan — Fierce Pharma
https://www.fiercepharma.com/pharma/novo-lilly-pit-their-glp-1s-against-one-another-diabetes-and-obesity-easd-kicks-milan
4. Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway | EurekAlert! — EurekAlert!
https://www.eurekalert.org/news-releases/1145489
5. Step Back: With an alleged counterfeit Ozempic smuggling scheme now under investigation, how can patients tell whether a GLP-1 prescription came through a legitimate, FDA-regulated supply chain—and what should they do if the packaging, pharmacy, or product seems suspicious?
Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com
29 Sept 2026
Zealand, Roche Start Petrelintide Phase 3 as 100% Pharma Tariffs Begin — September 29, 2026
Zealand Pharma and Roche have launched a roughly 7,000-person Phase 3 program for once-weekly petrelintide in obesity. Meanwhile, a baseline 100 percent Section 232 tariff on imported patented medicines and ingredients takes effect and EASD convenes in Milan.
In this episode:
Top stories:
1. Global Registrational Phase 3 ZUPREME Program Evaluating Petrelintide in Overweight or Obesity Initiated – Zealand Pharma - Medical Update Online — Medical Update Online
https://medicalupdateonline.com/2026/09/global-registrational-phase-3-zupreme-program-evaluating-petrelintide-in-overweight-or-obesity-initiated-zealand-pharma/
2. Navigating Pharma’s Forced Supply Chain Revolution - Chemistry Today — Chemistry Today
https://www.chemistry-today.com/articles/navigating-pharmas-forced-supply-chain-revolution/
3. EASD 2026 to Feature New Diabetes Approaches in T1DM, T2DM, obesity - Dagensdiabetes — Dagens Diabetes
https://dagensdiabetes.se/easd-2026-to-feature-new-diabetes-approachesin-t1dm-t2dm-obesity/
4. Republicans and Democrats Find a Unifying Target: Pharmacy Benefit Managers — KFF Health News
https://kffhealthnews.org/health-industry/pharmacy-benefit-managers-pbms-drug-costs-common-ground-tennessee/
5. Oral solid dose at a turning point: Scaling for the next generation of therapies - Pharmaceutical Technology — Pharmaceutical Technology
https://www.pharmaceutical-technology.com/sponsored/oral-solid-dose-scaling-for-the-next-generation-of-therapies/
Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com
28 Sept 2026
Mylan Tests Novo's Wegovy Patents as States Target Chinese GLP-1 Supply — September 28, 2026
Mylan is asking a Delaware court to clear its proposed generic Wegovy from a new Novo Nordisk patent. Twenty state attorneys general are warning the White House about Chinese GLP-1 ingredient suppliers, and doctors are flagging a rare vision-loss risk still under study.
In this episode:
Top stories:
1. Mylan asks US court to clear Wegovy generic from Novo patent claims | Reuters — Reuters
https://www.reuters.com/legal/legalindustry/mylan-asks-us-court-clear-wegovy-generic-novo-patent-claims-2026-09-25/
2. Step Back: Mylan is asking a court to clear a Wegovy generic from Novo Nordisk’s patent claims—what would a win actually change for patients, and why wouldn’t it automatically mean a generic could appear immediately?
3. Tennessee AG Skrmetti Joins 20-State Warning over Chinese Weight-Loss Drug Suppliers Linked to Fentanyl Precursors - Tennessee Star — Tennessee Star
https://tennesseestar.com/justice/tennessee-ag-skrmetti-joins-20-state-warning-over-chinese-weight-loss-drug-suppliers-linked-to-fentanyl-precursors/tpappert/2026/09/25/
4. Doctor warns of 'eye stroke' risk linked to GLP-1 weight loss drugs - Health - News - Daily Express US — Daily Express US
https://www.the-express.com/news/health/216811/eye-stroke-warning-glp1-drugs
Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com
25 Sept 2026
Mounjaro Misuse in Japan, Contraband GLP-1 Pens Flood Brazil — September 25, 2026
Mounjaro's off-label weight-loss use in Japan has drawn 35 suspected adverse-event reports, including pancreatitis and hypoglycemia. In Brazil, GLP-1 pen seizures in the first half of 2026 were 300% above all of 2025, as gray markets outpace regulated access.
In this episode:
Top stories:
1. Reported Adverse Effects of Maunzar in Japan: Hypoglycemia and Pancreatitis After Use for Weight Loss - The Asia Business Daily — The Asia Business Daily
https://www.asiae.co.kr/en/article/2026092316103578356
2. LatAm Trafficking of Contraband Weight Loss Drugs — InSight Crime
https://insightcrime.org/news/trafficking-of-contraband-weight-loss-drugs-from-paraguay-to-brazil-spikes/
3. Eli Lilly says Foundayo draws a third of new pill users | Mugglehead — Mugglehead
https://mugglehead.com/eli-lilly-foundayo-new-glp1-pill-patients-houston-plant/
4. AM Best highlights GLP-1 insurance cost pressures in podcast discussion — Traders Union
https://tradersunion.com/news/financial-news/show/3480035-glp-1-insurance-cost-pressures/
Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com
24 Sept 2026
Semaglutide heart signal meets FDA import and Medicare access shifts — September 24, 2026
Semaglutide researchers say SELECT’s heart benefit isn’t fully explained by weight loss, but the practical GLP-1 fight is still access, from FDA import restrictions and Medicare Bridge uptake to Novo’s pipeline and oral manufacturing plans. Ask your prescriber before changing treatment.
In this episode:
Top stories:
1. Weight loss alone does not explain lower heart disease for those on semaglutide | EurekAlert! — EurekAlert!
https://www.eurekalert.org/news-releases/1144558
2. China's Sinopep Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended — BigGo
https://finance.biggo.com/news/89ee3de0-c91d-4f7e-b274-473504ec25cd
3. Novo’s CagriSema beats lower-dose tirzepatide in diabetes, meets obesity endpoint — AllSci
https://allsci.com/news/clinical-trials/cagrisema-tirzepatide-type-2-diabetes-novos-tops/
4. 700,000 Seniors Start GLP-1 Weight-Loss Drugs — but US Taxpayers Cover $195 Per Patient | IBTimes UK — IBTimes UK
https://www.ibtimes.co.uk/700000-us-seniors-start-glp1-drugs-medicare-1821241
5. Novo aims for 10-fold increase in oral GLP-1 manufacturing capacity | Pharma Manufacturing — Pharma Manufacturing
https://www.pharmamanufacturing.com/facilities/article/55406864/novo-aims-for-10-fold-increase-in-oral-glp-1-manufacturing-capacity
Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com
Contact GLP-1 Daily
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of GLP-1 Daily?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
